MTAA
DIA
Market cap3.91bUSD
Jun 18, Last price
63.74EUR
1D
-1.27%
1Q
-0.03%
Jan 2017
13.32%
IPO
432.94%
Name
DiaSorin SpA
Chart & Performance
P/E
18.13
P/S
2.88
EPS
3.52
Div Yield, %
1.88%
Shrs. gr., 5y
0.34%
Rev. gr., 5y
10.90%
Revenues
1.19b
+3.20%
Net income
188m
+17.68%
CFO
359m
+15.12%
Dividend
May 19, 20251.2 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DiaSorin S.p.A. specializes in the creation, production, and global distribution of both immunodiagnostic and molecular diagnostic testing kits. Their extensive reach covers Europe, Africa, North, Central, and South America, the Asia Pacific region, and China. The company's offerings include a suite of immunodiagnostic LIAISON platforms, such as the LIAISON XS, LIAISON XL, and LIAISON XL LAS. For molecular diagnostics, they provide the LIAISON MDX system, which is utilized for amplifying nucleic acids to identify viruses in patient samples, thereby enabling the diagnosis of viral infections. DiaSorin has also established key collaborations: a partnership with QIAGEN focuses on a diagnostic solution for latent tuberculosis detection; another with TTP is for advancing molecular Point-of-Care solutions; and a third with MeMed aims to introduce a test capable of distinguishing between viral and bacterial infections. This enterprise, established in 1968, has its corporate headquarters situated in Saluggia, Italy.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||